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ABSTRACT:  
Enzymes that proceed through radical intermediates have a rich chemistry that includes 
functionalisation of otherwise unreactive carbon atoms, carbon-skeleton rearrangements, 
aromatic reductions, and unusual eliminations. Especially under anaerobic conditions, 
organisms have developed a wide range of approaches for managing these transformations 
that can be exploited to generate new biological routes towards both bulk and specialty 
chemicals. These routes are often either much more direct or allow access to molecules that 
are inaccessible through standard (bio)chemical approaches. This review gives an overview 
of some of the key enzymes in this area: benzoyl-CoA reductases (that effect the enzymatic 
Birch reduction), ketyl radical dehydratases, coenzyme B12-dependant enzymes, glycyl 
radical enzymes, and radical SAM (AdoMet radical) enzymes. These enzymes are discussed 
alongside biotechnological applications, highlighting the wide range of actual and potential 
uses. With the increased diversity in biotechnological approaches to obtaining these enzymes 
and information about them, even more of these amazing enzymes can be expected to find 
application in industrial processes. 
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Radical chemistry is extremely versatile in functionalizing otherwise unreactive molecules. 
This is specifically owed to the typically high reactivity of radical species, but often comes at 
the cost of poor regioselectivity and stereoselectivity, and the requirement for redox-active 
agents, such as potentially toxic metal complexes, to initiate the reaction. As such, radical 
chemistry has found utility in areas such as polymer production, where either the incipient 
radical or its reaction can be closely controlled, although reactions ranging from carbon-
carbon bond formation, carbon-heteroatom bond formation, cyclisations (including cascade 
cyclisations), rearrangements, and C-H bond cleavages are all well documented.[1] 
Nature has transcended the challenges of radical chemistry, whilst retaining the benefits of 
the broad range of reactivity, through enzymatic control. The chiral, three-dimensional 
structure of enzymes helps to specifically locate substrates in relation to radical activating 
agents and can thus control both the targeted bond (regio-control), and the stereochemical 
outcome of the radical process. Radical enzymes are likely to have had a significant 
contribution in directing chemistry in the pre-oxygen era,[2, 3] and continue to play 
important roles in life processes, such as in the synthesis of DNA precursors,[4] detoxifying 
the body,[5] degradation of biological materials,[6] carrying out oxidations and epoxidations 
in the production of metabolites,[7, 8] decarboxylation reactions of key metabolic 
pathways,[9, 10] and in many other biosynthetic pathways.[11-13] 
Practically, radical enzymes can be broken into two major classes; aerobic and anaerobic. 
Aerobic radical enzymes are typically oxidases, and utilise either oxygen or other reactive 
oxygen species to achieve their transformations. Examples of industrially-relevant aerobic 
radical enzymes include laccases,[14, 15] Cytochrome P450 enzymes (CYPs, P450s),[16-18] 
horseradish peroxidase,[19] and oxygenases,[20] with applications ranging from 

































































bioremediation, detoxification of wastewater streams, food preservation, fuel cells, and 
bleaching, to biosensors and diagnostics. Aerobic radical enzymes are thus well-established 
catalysts in biotechnology. 
Of increasing industrial interest are the anaerobic radical enzymes, especially for fine and 
bulk chemicals. Importantly, these enzymes have the potential to functionally modify a 
substrate without oxygen incorporation, requiring less (expensive) adaptation of downstream 
synthetic methodologies than from oxygen-rich biomass-derived feedstocks.[21] As such, 
anaerobic radical enzymes could either act as a bio-based stop-gap in catalytic schemes while 
other new synthetic approaches are more fully developed for these sustainable resources, or 
as a replacement for harsher chemical conversions. Anaerobic radical enzymes possess great 
scope, effecting hydrocarbon and aromatic reactions,[22-25] providing routes to methane 
activation[25] and heteroatom insertions,[26] and in the catabolism of amino acids to 
generate a broad range of branched and unbranched hydrocarbon chains.[12, 13] Investments 
in developing such reactions with anaerobic radical enzymes have been made by such well-
known companies (and their subsidiaries) as Cargill,[27, 28] Novozymes,[29, 30] BASF,[31-
35] Roche,[36-39] DuPont,[40-43] INVISTA,[44-46] and Ajinomoto,[47] amongst others. 
This review focuses on the current applications and prospects for anaerobic radical 
enzymes in biotechnology. Historically, relatively little had been known about these enzymes 
due to their sensitivity to oxygen, and thus the necessity of stringent handling conditions for 
purification, mechanistic study and further development. This capacity exists in only a few 
specialist groups around the world and had limited the extent of the data that was available. 
However, the increasing growth in genomic information, and identification of specific 
signatures for a number of classes of radical enzyme has led to an intensified awareness of 
the sheer range of enzymes now available.[48, 49] A flavour, therefore, of different enzyme 
types and their reactions is presented below to highlight this diversity. With the broadening of 

































































approaches to obtaining mechanistic and functional data on anaerobic radical enzymes, more 
of these underexploited biocatalysts can be expected to enter the biotechnology market in the 
future. 
 
2. General classes of anaerobic radical enzymes 
2.1 Iron-sulfur based enzymes 
Before the ‘Great Oxidation Event’,[50] the biologically induced enrichment of terrestrial 
oceans and atmosphere with dioxygen, reduced forms of minerals, such as those rich in 
sulfide and divalent ferrous iron, were prevalent. Initial prototype reactions may have 
occurred on exposed iron-sulfide mineral deposits, suggesting a route by which protein 
scaffolds could enhance these iron-sulfur-catalysed reactions to develop them into life-
processes, often referred to as the iron-sulfur world hypothesis.[51-53] Today, these 
anaerobic, radical-generating enzymes are often seen as a functional relic of this era, before 
the rapid genetic development of other forms of electron transport.[54] The fact that they 
still persist is indicative of the core reactions that these enzymes catalyse,[2] some of which 
are impossible to achieve without the extreme reactivity of radicals. 
2.1.1 Different types of cluster 
There are a range of iron sulfur clusters in enzymes with more than a single iron centre; 
Fe2S2, Fe3S4, Fe4S4, and Fe8S7/8 are typical as electron carriers.[55] Within proteins, such 
clusters are typically held in place by either cysteinyl or histidine residues, with aspartate, 
serine or backbone amide groups also acting as ligands. Of interest to radical enzymes are 
the ferrodoxin-like class of low-potential iron clusters, consisting of both Fe2S2 and Fe4S4 
(Figure 1). In Fe2S2 clusters, the iron atoms are bridged by the sulfide moieties, generating 
a butterfly-like structure. Such clusters are found in an oxidised divalent state, with no 
overall spin (singlet state, S=0), or reduced singly charged state with spin of either 1/2 or 

































































9/2. The observation has been made that these clusters can act as the basic unit for the 
assembly of larger clusters, although cluster biogenesis within enzymes is often 
complicated.[55, 56]  
[FIGURE 1] 
Fe4S4 clusters are cuboid in structure, with a broader range of oxidation states from zero to 
trivalent. Through complexation of three or four cysteine residues they are also able to 
impart structural stability, in addition to their chemical role. In general, low-potential iron 
sulfur clusters provide a highly reducing environment, with redox potentials normally 
between -200 to -650 mV, although this range is strongly dependent on the ligands 
surrounding the cluster.[57] It is these low potentials that facilitate the radical chemistry in 
the examples described below. 
2.1.2 Enzymatic Birch reduction 
One of the classic reactions of organic chemistry, the Birch reduction of aromatic rings 
was reported by the Australian chemist Arthur Birch in 1944.[58] This reaction is 
especially important in the production of functionalised cyclohexenyl derivatives, which 
are precursors for steroids and their analogues,[59] polyketide derivatives,[60] and Diels-
Alder reactions. 
Nature too utilises a birch-like reduction as part of the group of enzymes that are termed 
benzoyl-CoA reductases (EC 1.3.7.8 and 1.3.7.9).[61-63] The global importance of such 
enzymes comes from their role in the degradation of monocyclic aromatics in the 
environment under anaerobic conditions, including chemicals toxic to human health such 
as xylenes, ethylbenzene and benzenes.[64] More recently these enzymes have been shown 
to have a role in the degradation pathway of phthalates.[65] The extremely low potentials 
required to achieve reduction of the aromatic moieties are achieved by remarkable 
combination of iron sulfur chemistry with a combination of other metal ions, such as zinc, 

































































tungsten and molybdenum. These enzymes are proposed to catalyse a two-step reduction, 
leading to the dearomatisation of benzoyl derivatives, and formation of the diene 
derivatives in a reaction analogous to the synthetic birch reduction (Scheme 1a).[62, 66] 
[SCHEME 1] 
 
2.1.3 Aromatics as sources of hydrocarbon derivatives 
One example of the commercially-oriented utilisation of benzoyl CoA reductase, 
patented by INVISTA, comes in the production of 7-carbon containing chemicals from 
aromatics.[44] Here, a variety of synthetically useful building blocks, including pimelic 
acid, 7-aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine and 1,7-
heptanediol, are generated from aromatic derivatives by the creation of new biological 
pathways from existing enzymes. Specifically, pimeloyl-CoA is the common intermediate 
for these straight-chain derivatives, and this molecule is generated via a five-step enzymatic 
process from the benzoyl CoA precursor, which in turn is generated from chorismate 
through one of two different three-step enzymatic processes. The key reaction to ensure 
that the aromatic derivatives are amenable to linearization is carried out by benzoyl CoA 
reductase, where reduction of benzoyl CoA generates the cyclohexa-1,5-diene-1-
carboxyl-CoA derivative, which can be ring-opened after further oxidation (Scheme 1b). 
 
2.1.4 Ketyl radical dehydratases 
Dehydration of 1,3-ketoalcohols to generate alkenes through elimination is a classical 
reaction taught in high school and undergraduate chemistry classes, and central to fatty acid 
metabolism. The mechanism for dehydration of a 1,3-ketoalcohol relies on the increased 
acidity of the α-hydrogen, and thus stability of the intermediate carbanion via conjugation, 
to drive this reaction thermodynamically (Scheme 2a). For dehydrations of either 1,2- or 

































































1,4-ketoalcohol though, the hydrogen atom to be removed is not as acidic, eliminating the 
driving force and requiring nature to come up with an alternative approach.[67] For these 
reactions, a radical is proposed enact an umpolung reaction via an intermediate ketyl 
radical, which allows subsequent deprotonation and dehydration. The deprotonation in 1,2- 
and 1,4-dehydratases is typically initiated by a single electron reduction via either an 
‘Archerase’[68] or an FAD-dependent oxidation,[69, 70] respectively, both mediated with 
an Fe4S4 cluster. The ‘Archerase’ activators of 2-hydroxyacyl-CoA dehydratases are so 
named because they evoke the image of an archer in their action, shooting an electron into 
the dehydratase, driven by ATP hydrolysis. This electron, required for catalysis, is returned 
after each turnover back to the Fe4S4 of the enzyme (Scheme 2a(ii)), so only one shot of the 
archer is required to initiate many turnovers.  
[SCHEME 2] 
The characterised ketylalcohol dehydratases include: (R)-2-hydroxyglutaryl-CoA 
dehydratase (utilised in glutamate metabolism in Clostridia and Acidaminococcus, amongst 
others, EC 4.2.1.167),[71] lactyl-CoA dehydratase (EC 4.2.1.54), involved in lactate and 
amino acid fermentation, (R)-phenyllactyl-CoA dehydratase (phenylalanine, tyrosine and 
tryptophan degradation, EC 4.2.1.B25), (R)-2-hydroxyisocaproyl-CoA dehydratase (leucine 
fermentation, EC 4.2.1.157),[72, 73] and 4-hydroxybutyryl-CoA dehydratase (involved in a 
number of pathways, including metabolite degradation and CO2 fixation, EC 
4.2.1.120).[69] Very recently, the radical SAM (see section 2.4, below) dehydratase AprD4 
has also been proposed to catalyse the 1,2-diol dehydration of the antibiotic intermediate 
paromamine to 4'-oxolividamine via a ketyl radical-based mechanism.[74] 
2.1.5 Unsaturated organic acid synthesis and derivatives therefrom 
Applications of 2-hydroxyglutaryl-CoA dehydratase focus on the bioproduction of 
unsaturated dicarboxylic acids. BASF has patented glutaconate production utilizing a 

































































recombinant organism containing the enzyme, with feedstocks of either glutamate or 
glucose.[31] A similar approach to the bioproduction of adipic acid has also been 
described, relying on the broad substrate specificity of clostridial-derived 
2-hydroxyglutaryl-CoA dehydratase expressed in E. coli to generate the unsaturated adipic 
acid precursor, 2-hexenedioic acid.[75] 
Crotonyl-CoA is another target for the production of polymers and as an intermediate 
towards biofuels. Production of this derivative follows very similar biochemical routes to 
that for glutaconate, with the added step of the decarboxylation of the glutaconyl-CoA 
produced from 2-hydroxyglutaryl-CoA dehydratase before either deesterificaction,[76] or 
further biochemical transfo mations.[45, 77] 
The generation of a variety of 7-carbon containing chemicals useful for the production of 
nylons and related polymers has been described utilising 2-hydroxyglutaryl-CoA 
dehydratase.[46] Reduction of 2-hydroxypimeloyl-CoA to the corresponding unsaturated 
derivative 2(E)-heptenedioyl-CoA is carried out with the 2-hydroxyglutaryl-CoA 
dehydratase en route to either 2(E)-heptenedioate, pimeloyl-CoA or pimelate 
semialdehyde, which can be further functionalised.[46] Celexion take an alternative 
approach to generating related difunctional hexanes by claiming not only 
2-hydroxyglutaryl-CoA dehydratase, but also the ketyl-radical enzyme lactyl-CoA 
dehydratase,[78] as enzymes that can be used to convert 6-amino-2-hydroxyhexanoic acid 
(and/or the corresponding CoA ester) to (E)-6-aminohex-2-enoic acid, with subsequent 
hydrogenation to generate ε-aminocaproate. 
More commonly, lactyl-CoA dehydratase has been described in the production of for 
example 3-hydroxypropionic acid (3-HP) and other derivatives via the formation of an 
acryl-CoA (propenoyl-CoA) intermediate (Scheme 2b).[29, 45, 79-81] These 3-carbon 
units are extremely versatile for the production of a range of industrially useful building 

































































blocks, such as for example 1,3-propanediol (1,3-PD), methacrylic acid,[82] 1,3-butadiene, 
and this can be achieved in principle with relatively good conversions from lactate.[83] 
This type of conversion also gives access to these materials from a range of renewable 
resources including glucose,[27] and lignocellulosic biomass.[80] 
An alternative route to derivatives such as 1,3-butadiene can be achieved through 
crotonyl-CoA formed via the action of 4-hydroxybutyryl-CoA dehydratase, with an 
additional isomerisation from vinylacetyl-CoA delta isomerase (Scheme 2c).[45] Similarly, 
this reaction, has been the basis for biological routes to 1,3-butanediol,[84] methacrylic 
acid, and methacrylate esters. The production of 1,4-butanediol[85] suggests that the 
additional isomerase activity of 4-hydroxybutyryl-CoA dehydratase can be utilised to 
generate the 1,4 diol motif (Scheme 2d).[86] 
For these dehydratases, the selected examples above indicate the wide scope in the 
production of both bulk and specialty chemicals that is made accessible. They will certainly 
continue to play an important role in bioproduction for the foreseeable future. 
 
2.2 B12-dependent enzymes 
Coenzyme B12 (Figure 2a) is one of the more widely-studied radical generating agents in 
nature, having the unique feature of also being an organometallic.[87] Coenzyme B12 is one 
of the most complex cofactors, requiring over 30 biosynthetic steps to produce de 
novo.[88] The highly complex structure contributes to the electronic control over the bound 
cobalt and provides numerous points for biological recognition and specificity, helping to 
anchor the coenzyme in a precise position for generation of the highly reactive adenosyl 
radical intermediate. In fact, the tight control of this radical, and others involved in the 
reaction pathways, is a defining feature of B12-dependent enzymes, as many of the 
intermediates are both highly oxygen sensitive and extremely reactive.[89] 


































































2.2.1 Cofactor Chemistry 
The carbon-cobalt bond of coenzyme B12 is the defining catalytic motif from which 
the adenosyl radical (Ado•) is generated upon cleavage (Figure 2b). This cleavage is 
thought to be triggered upon binding of the substrate to the coenzyme-containing enzyme, 
induced by structural changes.[89] This ensures that the intermediate radicals are shielded 
from reactive oxygen species and other molecules that may interact with the highly reactive 
intermediate, and helps to ensure the recyclability of the cofactor. This approach for radical 
catalysis is thus practical for a range of specialist reactions of industrial interest, including 
carbon-skeleton rearrangements, aminomutases (Table 1) and eliminases (Table 2).  
[TABLE 1] [TABLE 2] 
 
2.2.2 1,3-Propanediol production 
The related enzymes diol dehydratase (EC 4.2.1.28) and glycerol dehydratase (EC 
4.2.1.30) catalyse the key step in the enzymatic generation of 1,3-propanediol (PDO or 1,3-
PD), from glycerol. In a process used by DuPont Tate&Lyle,[40],[41] more than 60,000 
tonnes/annum of this bio-generated material is produced and marketed as either Susterra
®
, 
with application to a number of industrial products such as polyurethanes, unsaturated 
polyester resins, engine coolants, and either heat-transfer, low-temperature food-safe, or 
deicing fluids; or as Zemea
®
 with food, personal care and pharmaceutical applications. 
Because the E. coli used in the biotransformation does not naturally produce the cofactor 
coenzyme-B12 de novo, the pathway for its synthesis is included in the modified organism. 
DuPont Tate&Lyle have also carried out cradle-to-gate LCA analyses to demonstrate the 
effectiveness in this bio-based process with respect to reduction of greenhouse gas 
emissions and non-renewable energy use, relative to the petroleum-based derivatives.[90] 

































































The radical-catalysed isomerisation of the 1,2-diol portion of glycerol to the corresponding 
aldehyde (3-HPA), followed by reduction, affords the 1,3-diol (Scheme 3). 
[SCHEME 3] 
The utility of this conversion for short-chain 1,2-diols means that diol dehydratase has 
also been employed in other reaction schemes for renewable bulk derivatives, including 
production of intermediates butanone (and thus also 2-butanol)[42] from 
2,3-butanediol,[43, 45, 91] propanal from 1,2-propanediol,[45] and many applications 
where 3-HPA is a desired intermediate.  
 
2.2.3 Branched to straight-chain derivatives 
B12-Dependant carbon-skeleton mutase enzymes take branched chain derivatives and 
convert them to straight chain derivatives for further metabolic processing (Table 1).[92] 
Characterised versions include methylmalonyl CoA mutase (EC 5.4.99.2), ethylmalonyl 
CoA mutase (EC 5.4.99.63), isobutyryl CoA mutase (EC 5.4.99.13), 
2-hydroxyisobutyryl-CoA mutase (EC 5.4.99.64), methylene glutarate mutase (EC 
5.4.99.4), and glutamate (methylaspartate) mutase (EC 5.4.99.1). Genomatica have also 
described the possibility of using isobutyryl-CoA mutase as a 4-hydroxybutyryl-CoA 
mutase via substrate promiscuity, en route to methacrylate,[82, 93] and isobutanol.[94] 
The ability to transform a carbon backbone is invaluable in the preparation of new 
chemicals. This is particularly highlighted through the deployment of the four-carbon 
precursor succinyl-CoA as a readily accessible intermediate to access the three-carbon 
precursor propanoyl-CoA, through initial conversion to the branched methylmalonyl-CoA 
using methylmalonyl-CoA mutase, followed by epimerisation and decarboxylation.[45] 
Genomatica describe the same initial steps, conversion of succinyl-CoA to 

































































methylmalonyl-CoA using the mutase, and subsequent epimerisation to access methacrylic 
acid via a range of routes.[82]  
Mutases are described extensively in a number of possible routes to the important bulk 
chemical methacrylic acid.[82] Glutamate mutase can be utilised to convert glutamate to 
3-methylaspartate, which after elimination of ammonia and subsequent decarboxylation 
can generate methacrylic acid. In another alternative approach that also utilises a mutase 
reaction 2-hydroxyglutarate is used as a substrate to generate the corresponding 
3-methylmalate, which is then similarly dehydrated to mesaconate and decarboxylated to 
methacrylic acid. Further, catalysis by 3-hydroxybutyryl-CoA mutase is described, in a 
route from acetyl-CoA, to generate 2-hydroxyisobutyryl-CoA, which, through subsequent 
radical-mediated dehydration, generates methacroyl-CoA as a methacrylic acid precursor. 
In another process starting from acetyl-CoA, isobutyryl-CoA mutase converts 
butyryl-CoA, generated from reduction of crotonyl-CoA, into isobutyryl-CoA, which is 
dehydrogenated to also form methacryl-CoA. These suggested transformations show how a 
full range of mutases can be creatively utilised to access similar building blocks from a 
wide range of starting carbon-chain lengths and configurations (Scheme 4). 
[SCHEME 4] 
The production of ethylmalonyl-CoA mutase has been described for the preparation of 
3-hydroxyisobutyric acid and related derivatives through a multistep pathway going 
through crotonyl-CoA.[95, 96] After carboxylation of crotonyl-CoA to form the 
ethylmalonyl-CoA, the mutase generates the corresponding methylsuccinyl-CoA, which is 
converted in three further steps to the propanoyl-CoA precursor. Alternative routes to the 
desired 3-hydroxyisobutyric acid, starting from different precursors, can also be achieved 
by utilizing either methylmalonyl-CoA mutase or isobutyryl-CoA mutase.[96] 

































































Mutases are described in the production of biofuel and small alcohols, with 
isobutyryl-CoA used particularly where introduction of a branched-chain is valuable.[97, 
98] Isopropanol can be produced from the appropriate four-carbon straight-chain CoA 
derivative.[98] Similarly, the bulk chemical n-propanol can be produced by the action of 
methylmalonyl-CoA mutase on succinyl-CoA. Here, the produced methylmalonyl-CoA is 
subsequently decarboxylated to form the propanoyl-CoA intermediate for n-propanol 
synthesis.[30] 
As can be seen, there is a strong contribution from B12-dependent enzymes in targeting 
highly relevant bulk chemicals, with a major facilitator of their biotechnological role being 
the close control of the radical. This control means that they are typically more resistant to 
oxygen than many other anaerobic radical enzymes,[12] and as such more robust to process 
conditions. Refinement of the activities, for example by selection of improved enzymes 
from alternate organisms, may provide further advances in the contributions of these 
enzymes to overcoming our reliance on oil-based technologies. 
 
2.3 Glycyl radical enzymes 
As an alternative to directly cofactor-generated radicals, the active radical required for 
catalysis can be harboured within the enzyme. This is the situation with glycyl-radical 
enzymes, where the radical is stored on the enzyme backbone, which is proposed to be then 
transferred to an active-site cysteine for active catalysis. Generation of this stable backbone 
radical is achieved through a family of radical SAM (see section 2.4)-activating 
enzymes,[99] that selectively abstract hydrogen from a semi-conserved motif (Table 
3).[100] This means that, for activity, both enzymes need to be present in any constructs 
that are developed, adding additional complexity to their deployment. For these enzymes, 

































































anaerobic conditions are essential as reaction of the glycyl radical with oxygen results in 
cleavage of the protein, and thus permanent inactivation. 
[TABLE 3] 
2.3.1 Scope of reactions 
Although the number of glycyl radical enzymes characterised to date is small, 
together they cover a range of useful reactivities. This includes carbon-carbon bond 
cleavage activities of pyruvate formate lyase (EC 2.3.1.54) and homologue 2-oxobutyrate 
formate lyase (EC 2.3.1.-); carbon-nitrogen bond cleavage catalysed by choline 
trimethylamine-lyase (EC 4.3.99.4); decarboxylation activity of 4-hydroxyphenylacetate 
decarboxylase (EC 4.1.1.83); the reductase activity of anaerobic ribonucleotide reductase 
(EC 1.1.98.6); the dehydratase activity of the B12-independent glycerol dehydratase (EC 
4.2.1.30), and recently uncovered 4-hydroxyproline dehydratase;[101] and carbon-carbon 
bond-forming reactions of benzylsuccinate synthase (EC 4.1.99.11) and 
methylpentylsuccinate synthase (EC 4.1.99.-). 
2.3.2 Hydrocarbon metabolism 
A significant industrially-relevant role of glycyl radical enzymes is in environmental 
protection, through the ability of benzylsuccinate synthase and methylpentylsuccinate 
synthase to degrade hydrocarbons under anaerobic conditions.[24] In each case, degradation 
of either toluene (and derivatives, including methylnaphthyl derivatives) or long chain 
saturated hydrocarbons (C6-C16) is achieved by first coupling to the double bond of 
fumarate through generating either a tolyl-based or 2-alkyl radical, respectively (Scheme 5). 
The resulting succinyl derivatives can then be further degraded through a series of standard 
anaerobic metabolic routes. Recent work to explore the extent to which these enzymes are 
found suggest that there should be ample scope to select systems compatible with the 
desired host environment.  


































































2.4 Radical SAM (Adomet radical) enzymes 
S-Adenosyl methionine is a key cofactor not only for heterolytic methylation, for which 
it is well known,[102] but also in the generation of substrate radicals via an adenosyl 
radical intermediate.[103] This mechanism for radical generation echoes that discussed 
above for the B12-dependent enzymes (Section 2.2), with these enzymes likely the earlier 
precursor of the complex B12 cofactor. As such, it has been designated the “poor-man’s 
B12” due to its relative simplicity,[104] although the range and scope of reactions 
uncovered to date for radical S-adenosyl methionine-dependent enzymes eclipses those of 
their B12-dependent cousins substantially. Currently there are around one hundred different 
enzyme subtypes recognised, with at least twenty more uncharacterised genetic 
groupings.[49] Recently, hybrid B12 (see section 2.2) / radical SAM enzymes have been 
attracting interest, although the detailed mechanisms of radical catalysis for these enzymes 
is only just emerging.[105] 
2.4.1 General chemistry 
All radical SAM enzymes share common features and thus some common chemistry, 
even though the variety of outcomes is expansive. The structural information to date 
highlights a common TIM-barrel structure, although this can vary between enzymes from a 
full-(β/α)8 barrel architecture to more common partial barrels (often (β/α)6) (Figure 
3a),[106] with size most often dependent on the substrate. The key motif is a CX3CXφC 
motif (with φ a conserved aromatic),[107] with these three cysteine residues being crucial 
for the recruitment of the Fe4S4 cluster, with the fourth site complexed to the sulfur of 
SAM. Other variations with different numbers of residues between the cysteines also exist, 
highlighting the diversity of primary structure utilised to generate this three-dimensional 
functional unit.  


































































The basic and common reaction catalysed by radical SAM enzyme is the cleavage of 
S-Adenosyl methionine to generate an adenosyl radical (Ado
•
) (Figure 3b), which 
subsequently abstracts a hydrogen atom from the substrate. Depending on the reaction 
outcome, either the AdoH product is regenerated to form the radical, and subsequently 
reconstitutes the cofactor (catalytic action), or the formation of product leaves AdoH as a 
by-product (cofactor action). 
Once hydrogen has been abstracted by the adenosyl radical, this is where the 
mechanisms of radical SAM enzymes diverge substantially. The catalysed transformations 
cover a huge range of radical chemistries, including sulfur insertions, decarboxylations, 
challenging methylations (including at phosphorous and unactivated carbon atoms), 
carbon-skeleton rearrangements, dehydrogenations, carbon-carbon coupling reactions, and 
others. As such, they show great potential for solving challenging chemical transformations 
through a biotechnological approach if they can be harnessed appropriately. The 
recognition of this potential is reflected by the significant interest in these enzymes in the 
patent literature, with highlights below. 
2.4.2 Antibiotic synthesis 
The problem of antimicrobial resistance (AMR) has been recognised as a serious 
global challenge by the World Health Organisation (WHO),[108] and many other research 
and health-related bodies.[109-112] The complex structures of many antibiotics, which 
often involve unusual methylations and C-C bond-forming reactions of amino-acid based 
and sugar-derived structures, offer a great synthetic challenge that has already been solved 
by the organisms that produce these antibiotics. As such, there is an increasing focus on 
pathways that exploit natural biosynthetic pathways for the bioproduction of both 
interesting antibiotics and their derivatives, access to the latter being especially important 

































































in combatting AMR. The examples below highlight the role of radical-generating enzymes 
and, in particular, rSAM enzymes in the transformations required to access this next 
generation of compounds to tackle AMR. 
Argyrins (Figure 4a) are a group of cyclic peptides consisting of eight amino acids 
first described by Vollbrecht et al.,[113] which have been shown to possess interesting 
immunosuppressive antibiotic activity.[114] Currently, they are mostly obtained from the 
natural producer organism Archangium gephyra as a mixture of different Argyrins. A 
patent for the biosynthetic pathway of Argyrins includes the genes for the whole pathway 
and provides the basis for manipulation of the synthetic pathway to produce Argyrins in 
micro-organisms.[115] It also includes the gene and amino acid sequence of the radical 
SAM enzyme Arg1. 
[FIGURE 4] 
The radical SAM-domain containing enzyme participating in the biosynthetic 
pathway is involved in the derivatisation of pre-Argyrin, catalysing the methylation of 
Argyrin A (R1=CH3) to Argyrin B (R1=C2H5), thus belonging to the class of methyl 
transferases. 
Nocathiacins (thiazole Nocardia streptozotocin, Figure 4b) belong to a class of 
cyclic thiazolyl peptide antibiotics first characterised 1998.[116] These highly modified 
sulphur-rich peptides have shown growth inhibition of Methicillin-Resistant 
Staphylococcus aureus (MRSA) and other antibiotic resistant bacteria.[117] Production 
of these antibiotics has been patented by Bristol Myers Squibb,[118-120] in addition to 
an available patent on structurally related antibiotics.[121] 
The cephalosporin Nocardia thiazole biosynthetic gene cluster consists of 37 genes 
in total and includes a gene encoding for a thiamine radical SAM synthetase. The rSAM 
enzyme encoded by the gene sequence Noc27 plays its role in a crucial rearrangement 

































































step during Nocathiacin biosynthesis. As shown in Scheme 6a, this rSAM enzyme 
catalyses the reaction of tryptophan to 3-methyl-indole-2-carboxylic acid during the 
biosynthesis of the crucial 5-methyl indole subunits incorporated into the Nocathiacin 
structures.  
[SCHEME 6] 
In the biosynthesis of the closely related thiopeptide antibiotic nosiheptide (Figure 
4c), a very similar rSAM enzyme is involved. A patent related to the biosynthesis of 
fluorinated nosiheptide derivatives describes the biotechnological fermentation synthesis 
of 3-methyl-2-indole acid and fluorinated derivatives thereof in E. coli. The radical SAM 
enzyme NosL could be successfully transferred from Streptomyces actuosus to E.coli and 
was shown to catalyse the synthesis of fluorinated 3-methyl-indole-2-carboxylic acid 
from fluorinated tryptophan.[122] The NosL enzyme has also recently been highlighted 
in terms of providing access to a wider pool of nucleoside-containing compounds.[123, 
124] 
Radical SAM enzymes are also involved in several steps of the biosynthesis of 
pactamycin (Figure 4d). This antibiotic belongs to the group of aminocyclitol antibiotics 
that are known for their high biological activity and which have been used as antibiotics 
for a long time, e.g. streptomycin, neomycin and gentamycin.[125] Pactamycin is 
structurally unique for an aminocyclitol antibiotic, by including two aromatic rings, a 
dimethylurea unit, and a five-membered aminocyclitol ring structure.[126, 127]  
A patent on the pactamycin biosynthetic gene cluster (the encoded proteins therein 
and their use)[128] from Streptomyces pactum contains four sequences encoding for 
radical SAM enzymes (PtmC, PtmH, PtmL, PtmM). While the roles of the individual 
radical enzymes in the pactamycin gene cluster are still not fully clear, it is believed that 
PtmH, -L, and –M are acting as C-methytransferases during the biosynthesis.  

































































Further, analysis of PtmC showed significant similarity to the radical SAM enzyme 
MitD (50% similarity) involved the biosynthesis of mitomycin.[129] Together with 
PtmG and PtmJ, PtmC is anticipated to be involved in the formation of a cyclopentitol 
derivative (Scheme 6b), resulting from initial deacylation, followed by a PtmC-catalysed 
radical rearrangement.  
Within a patent for a distinct peptide (phage) display[130] another radical SAM 
enzyme has been included. The patent for this modified peptide display makes claim on a 
genetic package displaying cyclic peptides that have “at least one intramolecular cyclic 
bond between two heteroatoms of amino acid side chains”.[130] To create this special 
peptide-display system, a set of post-translationally modifying (PTM) enzymes are used 
to modify the natural amino acids. One of them is the radical SAM enzyme TpdU. This 
enzyme is involved in the biosynthesis of another thiopeptide antibiotic thiomuracin 
(Figure 4e). Like the nocathiacins, thiomuracin also belongs to the class of macrocylic 
thiazolyl peptide antibiotics but with the special characteristic of a highly modified 
central six-membered heterocyclic ring system. The catalytic role of TpdU is as a C-
methytransferase during biosynthesis, through the methylation of thiazole.  
Radical enzymes are also involved in the biosynthesis of tunicamycin (Figure 4f) a 
fatty acyl nucleoside antibiotic containing uracil and N-acetylglucosamine (GlcNAc) 
moieties, which was first isolated in 1971.[131] The gene cluster for the biosynthesis of 
tunicamycins has been identified from Streptomyces chartreusis and patented.[132] The 
gene cluster contains only 14 genes of which two are thought to produce enzymes 
involved in radical reaction catalysis. TunB encodes for a radical SAM FeS-
Oxidoreductase that is proposed to catalyse the central C-C coupling between the 
galactosamine and uridine moieties, together with the Methyltransferase TunM. This 
mechanism has been proposed based on labelled precursor feeding experiments, 

































































however, there have been no additional, clear mechanistic studies that could yet fully 
confirm this process. 
The selected examples of patented radical SAM enzymes involved in the 
biosynthesis of various antibiotics gives an insight into possible broader industrially-
relevant synthetic applications. While many rSAM enzymes act as C-methyl 
transferases, others are involved in more complex crucial steps, such as heterocyclic ring 
rearrangements or C-C coupling reactions. Although many of the patented applications 
to date focus specifically on the preparation of a specific, biologically known antibiotic 
through its pathway (either in the native organism or via a production strain), the use of 
fluorinated substrates indicates already that there is some scope for a wider variety of 
derivatives to be prepared. Further enzyme evolution and engineering approaches 
therefore would logically be the next step in broadening the synthetic applicability of 
these enzymes further for the preparation of novel antimicrobial compounds. 
 
2.4.3 Amino acid production 
The DNA sequence coding for the radical SAM enzyme lysine-2,3-amino mutase (LAM) 
has already been patented in the US in 1999 for the biochemical synthesis of β-amino 
acids.[133] LAM converts L-α-lysine to L-β-lysine via a radical reaction mechanism, with 
the need for the additional cofactor pyridoxal phosphate (PLP). It is one of the better-
investigated radical enzymes, first purified 1970[134] and crystallised in 2005.[135] The 
active role of PLP in 1,2-amino migrations was in particular investigated by Han and 
Fry[136]. Fry also claimed the patent and has been involved in many aspects of 
understanding the function of LAM. The reaction mechanism of LAM is meanwhile well-
understood and verified. It undergoes a classical catalytic cycle with S-adenosylmethionine 
(SAM) being regenerated as a cofactor.  

































































Lysine binds in LAM as an aldimine adduct of PLP. Upon a one electron transfer from 
the central iron sulfur cluster to SAM the active radical species dAdo
•
 is formed, which 
subsequently abstracts the 3-pro-R hydrogen from the bound lysine. The subsequent radical 
rearrangement goes via an azacyclopropylcarbinyl ring formation and ring-opening, 
followed by re-abstraction of a hydrogen atom from dAdoH to form the β-amino acid 
product and close the catalytic cycle. 
Even though this patent was meant to be used as an alternative synthesis of L-β-lysine, it 
has not been industrialised until now. The many challenging requirements for this enzyme, 
like the need for anaerobic handling due to disruption of the central iron sulfur cluster 
under oxygen, and the need for the additional cofactor PLP, does not make it commercially 
viable at this stage. 
Due to the discovery and structural characterisation of 2,3-lysine aminomutase, the 
interest in other amino mutases for the production of β-amino acids has increased. Two 
more recent patents claim for the disclosure of gene sequences encoding for alanine 2,3 
aminomutase[28] and glutamate 2,3 aminomutase activity.[137] Both enzymes have not yet 
been characterised structurally, but direct transformation of α- to β-amino acids could be 
verified in both cases. Based on sequence comparisons and evidence for radical 
intermediates, Ruzicka and Frey directly describe glutamate-2,3-aminomutase as a radical 
SAM enzyme similar to LAM but with no activity toward lysine.[138] This 
characterisation has not been presented for alanine-2,3-aminomutase. Further, the patent for 
the non-natural alanine-2,3-aminomutase is specifically linked to the biosynthesis of 3-
hydroxypropionic acid (3-HP). The biosynthesis of 3-HP goes through a beta-alanine 
intermediate, which is normally rather inefficient for biotechnological applications using 
high value precursors (see Ref.[28]) but the patent describes direct amino mutase activity 
on L-α-alanine. 


































































2.4.4 Fine chemicals manufacture 
The biotechnological usage of a genetically modified bacterium belonging to the genera 
Methylobacterium or Hyphomicrobium for the production of Pyrroloquinoline Quinone 
(PQQ) has been patented in 2013.[47] The patent claims improved PQQ biosynthesis via 
enhanced expression of the responsible pqq gene cluster in these bacteria. 
PQQ is an essential redox cofactor for various bacterial dehydrogenases such as glucose 
and methanol dehydrogenase. It is mainly found in gram-negative bacteria, but could also 
be detected in high concentration in breast milk and mouse studies indicate an essential role 
for proper development and growth.  
The biosynthetic pathway of PQQ is still not completely understood, but it is known that 
this cofactor is derived from the amino acids tyrosine and glutamic acid that are present in 
a small peptide (23 to 39 amino acids depending on organism) thought to be both the 
precursor of PQQ and donor of the amino acids needed.[139] Also here, a radical SAM 
enzyme plays a crucial role during biosynthesis. PqqE (EC 5.-.-.-) is thought to catalyse 
another radical C-C bond formation between the two amino acids (Scheme 6c). However, 
the detailed mechanism is still far from clear. In particular it could be demonstrated that 
PqqE is directly interacting with PqqD but the role of this interaction remains unclear.[140] 
One hypothesis is that PqqD may influence the active site of PqqE in order to position the 
5'-deoxyadenosyl radical for the subsequent hydrogen abstraction from the tyrosine residue 
in PqqA. 
Lipoic acid is a sulfur-containing cofactor essential in organisms that undergo aerobic 
respiration, behaving as an electron acceptor in oxidative reactions, such as 
decarboxylation or carbon-carbon bond cleavage.[141] It has a particular role in amino acid 
degradation, and has additionally been highlighted as an excellent antioxidant. The 

































































mechanism biosynthesis of this molecule by the radical SAM enzyme LipA (EC 2.8.1.8) 
has attracted a significant degree of attention as it involved insertion of two sulfur atoms in 
an otherwise unactivated carbon backbone chain, a highly chemically challenging reaction 
(Scheme 6d).[26, 142-144] Structural and kinetic evidence has been provided that at least 
one, and probably both, sulfur atoms are derived from an auxiliary Fe4S4 cluster located 
near the N-terminus of the LipA enzyme,[141, 142, 145-147] meaning that reconstitution of 
this cluster limits the turnover.  
Interest in both the manufacture[148, 149] and cellular up-regulation of lipoic acid has 
been described,[33, 150-153] the latter with a view to either improving other cellular 
processes by improving the metabolism of production organisms, or with the specific aim 
of branched-chain fatty acid synthesis.[154] Synthesis and isolation of lipoic acid is an 
attractive target, since current chemical approaches suffer from production of racemates, 
poor yields and are not economic.[148] As such biological routes offer the opportunity for 
enantiomerically pure production with improvements in process conditions.[149] Such a 
route has been disclosed reporting potentially more than twice the wild-type activity, with a 
relatively low incubation temperature of between 25-30 °C, achieved through the cloning 
of the relevant genes (including FeS cluster assembly/repair genes) in an acid tolerant 
host.[148] Examples of Gluconobacter sp. and Saccharomyces sp., amongst others, are 
provided, with the target of extracellular production to facilitate isolation by crystallisation. 
More recently, expression of relevant genes has been achieved in an E. coli construct and 
the associated patent claims the use of low-value raw materials and improved 
environmental outcomes.[149] Here, metK, a gene involved in SAM biosynthesis, was also 
upregulated to ensure that a ready supply of the cofactor was available, since each 
conversion to lipoic acid requires two molecules of SAM.[143] The disclosure claims a 
more than 200-fold improvement in lipoic acid production (1.4 - 2.1 mgL
-1
, dependant on 

































































strain and conditions), as measured by UV-vis monitored HPLC, over the corresponding 
wild-type strain (0.005 mgL
-1
). 
Another essential sulfur-containing cofactor, biotin (vitamin B7 or vitamin H), is an 
excellent target for biochemical manufacture, being used in vitamin food supplements, as a 
medical-grade pharmaceutical, and primarily for the enhancement of animal feed. Current 
production is mainly met through chemical synthesis, with similar challenges faced as in 
the production of lipoic acid, namely with enantiopurity and environmental issues being of 
paramount concern. In nature, only small quantities of biotin are required, meaning that 
production tends to be low in host organisms. The major bottleneck to improving 
biosynthetic production is the radical SAM enzyme BioB (EC 2.8.1.6),[36] with an in vivo 
rate reported of around 0.1 min
-1
.[155] Given that this is comparable to the burst kinetics 
measured for the initial turnover (0.12 min
-1
),[156] this implies that the rate limiting step is 
indeed the sulfur insertion reaction catalysed by BioB, rather than due to the slowness of 
the repair mechanism that is required to reconstitute the Fe2S2 auxiliary cluster 
cannibalized to provide the sulfur required for the reaction (Scheme 6e).[157]  
To overcome the limitations of low biotin production, a number of approaches are 
disclosed in the patent and public literature, utilising different organisms. The E. coli system 
is the best studied to date,[32, 34, 35, 38, 39, 158-160] however, biotin overproduction has 
also been described in other organisms including Agrobacterium sp.,[159] Bacillus 
sphaericus (including chemically-induced mutants),[160] Bacillus subtilis,[36, 161] 
Brevibacterium flavum,[162] Kurthia sp.,[37] Pseudomonas mutabilis,[158] Serratia 
marcescens,[163-165] Sphingomonas sp.,[166, 167] the yeast Candida utilis,[168] and 
plants.[169] Many of the genetic manipulations centre upon modification of the expression 
systems and genes for proteins upstream from BioB, and/or inclusion of BioB from 
organisms other than the host organism. Using these approaches, production of biotin in 

































































levels ranging from 1.27 mg/L to 68 mg/L (up to 18-fold higher than controls),[166] and even 
around 15 g/L of 95% biotin,[158] have been claimed. In vitro use of purified BioB has also 
been carried out,[39, 159] and requires inclusion of repair enzymes and/or flavodoxins, to 
carry out this complex reaction. Interestingly, the rate constant ranges disclosed for the in 
vivo systems of 0.56-2.5 min
-1
,[166] including for mutants of BioB,[167] suggest that 
evolution, by generating a selection of modified BioBs either naturally or in an engineered 
fashion, may overcome some of the limitation on throughput, and be one of a number of 
useful approaches for industrial production in the future.  
 
2.4.5 Antiviral applications 
A Chinese patent claims for the preparation and application of an expression vector for 
the antiviral protein Viperin.[170] Applied in form of direct injection into fish, an increased 
antiviral potency of the fish was described.  
Viperin itself is a protein containing a SAM binding domain,[171] and a recent crystal 
structure confirms that the active site is structurally similar to other radical-SAM enzymes 
and binds SAM.[172] Viperin interacts with farnesyl diphosphate synthase (FPPS) in the 
cell, an enzyme essential in isoprenoid biosynthesis and thus involved in steroid 
synthesis.[173] It also catalyses the central reductive cleavage of SAM, indicating that 
viperin exhibits radical SAM chemistry for its antiviral activity.  
Very recently, Makins et al.[174] showed that over-production of viperin indeed 
reduces the rate of accumulation of FPPS, however, it does not influence the activity of 
FPPS. Further, they could demonstrate that mutating central cysteine residues of the FeS 
binding region does not have a negative effect on the reduction of FPPS levels in the cell 
which gives a clear indication that viperin does not act as a radical SAM enzyme in respect 
to FPPS regulation. Still unclear is if radical chemistry plays a role in other potential 
regulatory effects by viperin, although the recent structure suggests that the substrate may 

































































be a nucleotide triphosphate derivative,[172] very recently supported by EPR and 
modelling studies that identify UDP-glucose as a substrate.[175] 
 
2.4.6 Hyperphotosynthesis 
An engineered photosynthetic cell, with increased industrial fitness such as improved pH, 
salt and temperature tolerance, has been claimed by Joule Biotechnologies, Inc.[176] 
Although radical SAM enzymes are involved in various steps of the biosynthesis of 
coproporphyrinogen-III (an intermediate in chlorophyll production) through the enzyme 
HemN (EC 1.3.99.22),[3] and the radical SAM enzyme BChE is involved in 
bacteriochlorophyll biosynthesis,[177] this disclosure lists an alternative set of enzymes 
containing radical SAM domains. There is little detailed information provided on the 
identified radical SAM enzymes, with the exception of CfR (EC 2.1.1.224),[178] which 
belongs to the group of radical S-adenosyl-methyltransferases, and a highlight of a B12/radical 
SAM enzyme, also likely to be involved in methyl transfer. A number of other non-radical 
SAM methyltransferases are also listed, involved either in nucleotide methylation or the 
biosynthesis of B12. This suggests a primary role for radical SAM enzymes in this patent 
related to improvements in nucleotide methylation, including ribosomal RNA, related to 
enhanced protein production in vivo. 
 
3. Future prospects 
Radical enzymes have already demonstrated a broad scope in terms of applicability to 
industrial challenges, including the production of bulk chemicals, fine chemicals and much-
needed antibiotics. Remaining is the incorporation of many of these enzymes into scaled-up 
and economically competitive processes, such as has been possible for the best commercially 
exploited example, the synthesis of 1,3-PD.[40],[41] Here, many current and burgeoning 

































































technologies are likely to play a strong role in developing these enzymes further. At the 
forefront, particularly in the radical field, must be the consideration of computational 
approaches, since these can not only be utilised cheaply as screening methodologies, but are 
particularly appropriate to the more oxygen-sensitive enzymes, as they by-pass the need for 
anaerobic handling. An additional advantage comes when coupling with the vast increase in 
genomic information; enzymes from difficult hosts can be examined, unknown radical 
enzymes can be uncovered from their genetic signatures, and mechanistic information across 
species can be pooled. Developments in the area of computer-led design therefore offer much 
promise, particularly when coupled either in experimental feedback loops, or with 
information from complementary experimental approaches such as directed evolution. 
One of the most important aspects to ensure that radical enzymes reach their desired impact 
in industrial applications already shines through the above-described examples. More than for 
any other enzyme class, the current lack of detailed mechanistic understanding limits our 
potential for both improving and engineering these kinds of enzymes. Many of the examples 
included here often recognise radical enzymes as key catalysts, although their detailed 
function remains unclear. The difficulties in laboratory handling of the enzymes, resulting in 
limited high level mechanistic studies from just a few expert groups in the world, means that 
best use has been made of only a limited set of well-characterised radical enzymes. Here, the 
combination of advanced and steadily improving laboratory techniques, combined with the 
predictive computational approaches highlighted above, could mark a game-changing 
approach in the development of stainable (bio-)synthetic approaches incorporating radical 
enzymes in key catalytic reaction steps in near future. 
Through mechanistic understanding, both at the single-enzyme and cross-genome level, 
specific targets such as directed broadening of substrate specificity, reduction in oxygen 
sensitivity to reduce the need for stringent process conditions, and improvements in reaction 

































































rate, are made a possibility. Other areas for focus include fuller investigation of the enzyme 
activation repair mechanisms, such that these coupled processes can be carried out more 
efficiently in either cellular or multi-enzyme in vitro systems. Certainly, there is much work 
ahead for a full exploitation of anaerobic radical enzymes in the same way that is seen for 
other classes of enzyme today. Yet, as more interest is shown in these unique enzymes, a 
significant impact on the areas of applicability will no doubt follow. 
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Figure 1. The Fe2S2 (butterfly-like structure, left) and Fe4S4 (cubane-like structure, right) 
iron sulfur clusters are important to many radical-based enzymatic reactions. 
 
Figure 2. (a) The organometallic coenzyme B12 features a corrin ring and an adenosyl moiety 
(R) bound to cobalt, poised to form (b) the reactive 5'-adenosyl radical (Ado•), which is an 
important radical catalyst generated in both B12-dependant enzymes and radical SAM 
enzymes. 
 
Figure 3. The structures of radical SAM enzymes show a distinctive TIM-barrel architecture 
(a), with either a full-(β/α)8 barrel (left, biotin synthase, pdb ID 1R30, with second monomer 
of the dimer structure transparent) or, more commonly, a partial-(β/α)6 barrel (right, pyruvate 
formate lyase activating enzyme, pdb ID 3C8F). The common Fe4S4 motif is highlighted as 





Figure 4. Antibiotic scaffolds naturally fabricated with the help of radical enzymes in key 
steps of biosynthesis. (a) The cyclic peptides Argyrins are antimicrobials obtained from 
Archangium gephyra. Argyrin B (R1=CH2CH3) is synthesised via a radical-SAM mediated 
methylation of Argyrin A (R1=CH3). (b) The antimicrobial Nocathiacin contains a modified 
indole ring, derived from the radical-SAM mediated rearrangement of tryptophan. (c) The 
thiazole antibiotic nosiheptide has a key biosynthetic step catalysed by the radical enzyme 
NosL to generate the substituted indole ring. (d) Pactamycin is biosynthesised with the 

































































involvement of a number of different radical enzymes. (e) The antimicrobial secondary 
metabolite Thiomuracin A involves a radical methyltransferase in its synthesis. (f) Formation 
of the glycosidic antibiotic tunicamycin is thought to involve radical-SAM enzymes in the 
central C-C coupling between the sugar units. 
  



































































Scheme 1. Conversion of benzoyl-CoA to the diene derivative is proposed via the enzymatic 
Birch reduction, catalysed by benzoyl-CoA reductase. (a) The initial single electron reduction 
occurs at -1.9 V, compared with the -3 V required for the chemical birch reduction of 
benzene.[66] (b) Diene formation opens up the possibility for further functionalisation 
leading to ring cleavage, to form pimeloyl-CoA.[44] 
 
Scheme 2. Dehydration of ketoalcohols is a generally important reaction. (a) The general 
mechanism differs depending on the location of the alcohol i.) an example of simple base-
catalysed dehydration of a 1,3-ketoalcohol. ii.) an example of the proposed mechanism for 
dehydration of a 1,2-ketoalcohol, as might be expected for 2-hydroxyglutaryl-CoA 
dehydratase, proceeding through an umpolung reaction via a ketyl-radical intermediate. (b) 
Lactoyl-CoA dehydratase forms the precursor molecule propenoyl-CoA, which can undergo 
further conversion into a range of highly useful synthetic building blocks including 1,3-
propanediol (1,3-PD), butadiene, 3-hydroxypropanoic acid (3-HP) and methacrylic acid. (c) 
Formation of crotonyl-CoA through dehydration of 4-hydroxybutyryl-CoA using 
4-hydroxybutyryl-CoA dehydratase and subsequent isomerisation. (d) Isomerisation of 
crotonyl-CoA is also catalysed by 4-hydroxybutyryl-CoA dehydratase, and can be used to 
generate the 1,4-oxygenation motif required for the production of 1,4-butanediol.  
 
Scheme 3. Formation of the bulk chemical 1,3-propanediol (1,3-PD) from glycerol through 
radical-catalysed dehydration by B12-dependant dehydratase. 
 

































































Scheme 4. Routes to methacrylic acid have been proposed using a number of carbon-skeleton 
mutases. 
 
Scheme 5. (a) Aromatic and (b) long-chain hydrocarbons can be coupled to succinate as part 
of initial steps towards degradation.[22, 24] 
 
Scheme 6. Example radical-SAM catalysed reactions. (a) The radical rearrangement of 
tryptophan, catalysed by the enzyme Noc27, to generate the key 5-methyl indole intermediate 
in the biosynthesis of nocathiacin. (b) Suggested synthesis of the cyclopentitol intermediate 
that forms the core of the pactamycin structure, first through PtmG-catalysed deacylation 
followed by a radical rearrangement mediated by PtmC. (c) The radical-SAM enzyme PqqE 
is involved in the C-C bond coupling required to generate the ring structure of the cofactor 
PQQ. (d) Sulfur is inserted into the otherwise unactivated carbon backbone of octanoic acid 
through the action of LipA. The sulfur atoms derive from a Fe4S4 cluster within LipA, which 
must be regenerated after reaction. (e) The reaction of dethiobiotin (DTB) with the radical-
SAM enzyme BioB. The substrate radical reacts with the auxiliary enzyme-bound Fe2S2 
cluster, with subsequent hydrogen abstraction by a second adenosyl radical resulting in 
sulfur-ring formation to form biotin. 
  


































































Table 1. Key B12-dependant mutases and their reactions. 
Enzyme name Reaction catalysed EC reference 
Carbon skeleton mutases   
Isobutyryl CoA mutase 
 
5.4.99.13 
2-Hydroxyisobutyryl CoA mutase 
 
5.4.99.64 
2-Methylene glutarate mutase 
 
5.4.99.4 
Methylmalonyl CoA mutase 
 
5.4.99.2 
















































































Table 2. Key B12-dependant eliminases and their reactions. 


















-RVSGYAV-  Pyruvate formate lyase (PFL) 
-RVAGYSA-
†
  Choline trimethylamine lyase (CTL) 
-RVAGYSD-
‡
  trans-4-Hydroxy-L-proline dehydratase (t4LHypD) 
-RXCGYLG- X = V or T Class III ribonucleotide reductase (RNR) 
-RVAGXSZ- X = Y or F; Z = A, D or V B12-independent glycerol dehydratase (GDH) 
-RVAGXZB- X = Y or F; Z = S or T; B = A, D or G 4-Hydroxyphenylacetate decarboxylase (HPAD) 
-RXZGBSJ- X = V or T; Z = A or S; B = Y or F; J = A or D Benzyl Succinate Synthase (BSS) 
†
Obtained through BLAST search of the Desulfovibrio alaskensis choline trimethylamine lyase, followed by 
multiple sequence alignment using Clustal Omega on sequences defined as choline trimethylamine lyase (>80% 
sequence identity).  ‡Obtained using the same methodology as for CTL, using the base sequence Uniprot ID 
A0A031WDE4,[101] with Clustal Omega on sequences identified with >77% sequence identity. 
 
  


































































Radicals offer the possibility of unique and efficient chemical transformations, if properly 
controlled.  Nature can provide this control in the form of enzymes, and this review provides 
an overview of the types of enzymes characterised, their current applications in 
biotechnology, and future directions to better exploit these fascinating catalysts. 



































































Figure 1. The Fe2S2 (butterfly-like structure, left) and Fe4S4 (cubane-like structure, right) iron sulfur 
clusters are important to many radical-based enzymatic reactions.  
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Figure 2. (a) The organometallic coenzyme B12 features a corrin ring and an adenosyl moiety (R) bound to 
cobalt, poised to form (b) the reactive 5'-adenosyl radical (Ado•), which is an important radical catalyst 
generated in both B12-dependant enzymes and radical SAM enzymes.  
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Figure 3. The structures of radical SAM enzymes show a distinctive TIM-barrel architecture (a), with either a 
full-(β/α)8 barrel (left, biotin synthase, pdb ID 1R30, with second monomer of the dimer structure 
transparent) or, more commonly, a partial-(β/α)6 barrel (right, pyruvate formate lyase activating enzyme, 
pdb ID 3C8F). The common Fe4S4 motif is highlighted as spheres. (b) Cleavage of Fe4S4-bound S-
adenosylmethionine to generate the 5'-adenosyl radical (Ado•).  
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Figure 4. Antibiotic scaffolds naturally fabricated with the help of radical enzymes in key steps of 
biosynthesis. (a) The cyclic peptides Argyrins are antimicrobials obtained from Archangium gephyra. Argyrin 
B (R1=CH2CH3) is synthesised via a radical-SAM mediated methylation of Argyrin A (R1=CH3). (b) The 
antimicrobial Nocathiacin contains a modified indole ring, derived from the radical-SAM mediated 
rearrangement of tryptophan. (c) The thiazole antibiotic nosiheptide has a key biosynthetic step catalysed 
by the radical enzyme NosL to generate the substituted indole ring. (d) Pactamycin is biosynthesised with 
the involvement of a number of different radical enzymes. (e) The antimicrobial secondary metabolite 
Thiomuracin A involves a radical methyltransferase in its synthesis. (f) Formation of the glycosidic antibiotic 
tunicamycin is thought to involve radical-SAM enzymes in the central C-C coupling between the sugar units. 
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Scheme 1. Conversion of benzoyl-CoA to the diene derivative is proposed via the enzymatic Birch reduction, 
catalysed by benzoyl-CoA reductase. (a) The initial single electron reduction occurs at -1.9 V, compared with 
the -3 V required for the chemical birch reduction of benzene.[66] (b) Diene formation opens up the 
possibility for further functionalisation leading to ring cleavage, to form pimeloyl-CoA.[44]  
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Scheme 2. Dehydration of ketoalcohols is a generally important reaction. (a) The general mechanism differs 
depending on the location of the alcohol i.) an example of simple base-catalysed dehydration of a 
1,3-ketoalcohol. ii.) an example of the proposed mechanism for dehydration of a 1,2-ketoalcohol, as might 
be expected for 2-hydroxyglutaryl-CoA dehydratase, proceeding through an umpolung reaction via a ketyl-
radical intermediate. (b) Lactoyl-CoA dehydratase forms the precursor molecule propenoyl-CoA, which can 
undergo further conversion into a range of highly useful synthetic building blocks including 1,3-propanediol 
(1,3-PD), butadiene, 3-hydroxypropanoic acid (3-HP) and methacrylic acid. (c) Formation of crotonyl-CoA 
through dehydration of 4-hydroxybutyryl-CoA using 4-hydroxybutyryl-CoA dehydratase and subsequent 
isomerisation. (d) Isomerisation of crotonyl-CoA is also catalysed by 4-hydroxybutyryl-CoA dehydratase, 
and can be used to generate the 1,4-oxygenation motif required for the production of 1,4-butanediol.  
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Scheme 3. Formation of the bulk chemical 1,3-propanediol (1,3-PD) from glycerol through radical-catalysed 
dehydration by B12-dependant dehydratase.  
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Scheme 4. Routes to methacrylic acid have been proposed using a number of carbon-skeleton mutases.  
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Scheme 5. (a) Aromatic and (b) long-chain hydrocarbons can be coupled to succinate as part of initial steps 
towards degradation.[22, 24]  
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Scheme 6. Example radical-SAM catalysed reactions. (a) The radical rearrangement of tryptophan, catalysed 
by the enzyme Noc27, to generate the key 5-methyl indole intermediate in the biosynthesis of nocathiacin. 
(b) Suggested synthesis of the cyclopentitol intermediate that forms the core of the pactamycin structure, 
first through PtmG-catalysed deacylation followed by a radical rearrangement mediated by PtmC. (c) The 
radical-SAM enzyme PqqE is involved in the C-C bond coupling required to generate the ring structure of the 
cofactor PQQ. (d) Sulfur is inserted into the otherwise unactivated carbon backbone of octanoic acid through 
the action of LipA. The sulfur atoms derive from a Fe4S4 cluster within LipA, which must be regenerated 
after reaction. (e) The reaction of dethiobiotin (DTB) with the radical-SAM enzyme BioB. The substrate 
radical reacts with the auxiliary enzyme-bound Fe2S2 cluster, with subsequent hydrogen abstraction by a 
second adenosyl radical resulting in sulfur-ring formation to form biotin.  
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